Revenue
2018
2019
2020
2021
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | £18.38B | £19.85B | £21.66B | £18.45B | £13.66B | £13.36B | £14.93B | £15.25B | £15.04B | £13.21B |
| Research & development | £43.0M | £32.0M | £23.0M | £11.0M | £12.0M | £9.0M | £19.0M | £13.0M | £14.0M | £19.0M |
| Operating expenses | — | — | — | — | £11.88B | £11.76B | £12.06B | £11.76B | £11.83B | £9.99B |
| Operating income | £4.93B | £4.47B | £4.88B | £4.37B | £2.40B | £2.28B | £2.87B | £3.49B | £3.21B | £3.23B |
| EBITDAderived | — | — | — | — | — | — | — | £5.02B | £4.69B | £4.54B |
| Net income | £2.90B | £2.29B | £7.80B | £2.35B | £1.64B | £1.26B | £1.51B | £3.55B | £7.79B | £2.59B |
| Basic EPSper diluted share | £0.62 | £0.57 | £1.97 | £0.65 | £0.47 | £0.37 | £0.45 | £1.03 | £2.07 | £0.69 |
| Diluted EPSper diluted share | £0.61 | £0.57 | £1.96 | £0.65 | £0.46 | £0.36 | £0.44 | £1.02 | £2.06 | £0.68 |